Fusion Antibodies Ltd (FAB) ORD GBP0.04
- Add to watchlist
- Create an alert
- This stock can be held in a
Share news, reports & tips
-
Fusion Antibodies reports positive recent trading
8 October 2024 15:40
(Sharecast News) - Fusion Antibodies reported positive trading in an update on Tuesday, highlighting significant progress for the first half of its financial year.
-
Fusion Antibodies strengthens financial position despite revenue decline
5 September 2024 13:53
(Sharecast News) - Preclinical antibody discovery and engineering specialist Fusion Antibodies said in its final results on Thursday that despite a challenging year with a decline in revenue, it had...
-
Fusion Antibodies 'on track and on plan' following positive Q1 performance
4 July 2024 09:50
(Sharecast News) - Antibody discovery specialist Fusion Antibodies said on Thursday that it was both "on track and on plan" following "positive momentum" throughout Q1.
-
Fusion Antibodies gets first order under new services agreement
27 February 2024 13:15
(Sharecast News) - Fusion Antibodies announced the receipt of its first purchase order under a master services agreement on Tuesday, which it agreed with a prominent diagnostics company on 14 February.
-
Fusion Antibodies raises £1.38m as it seeks new customers
14 February 2024 12:52
(Sharecast News) - Pre-clinical antibody specialist Fusion Antibodies announced a conditional fundraising of £1.38m before expenses on Wednesday, to help it target mo re industry conferences and customers...
-
Fusion Antibodies confirms £0.28m tax credit
1 February 2024 16:27
(Sharecast News) - Preclinical antibody discovery specialist Fusion Antibodies announced the successful receipt of a research and development tax credit from HMRC on Thursday.
-
Fusion Antibodies revenue falls, losses widen in first half
4 December 2023 12:01
(Sharecast News) - Contract research organisation Fusion Antibodies reported first-half revenue of £0.54m on Monday, down from £1.9m a year earlier.
-
Fusion Antibodies appoints interim finance chief
24 August 2023 14:45
(Sharecast News) - Preclinical antibody developer Fusion Antibodies announced the immediate appointment of Stephen Smyth as its interim chief financial officer on Thursday.
-
Fusion Antibodies progresses AI antibody collaboration
21 August 2023 13:43
(Sharecast News) - Preclinical antibody discovery specialist Fusion Antibodies updated the market on its 'AI/ML-Ab', or AIM-Lab, service on Monday.
-
Contract suspensions see Fusion Antibodies warn on revenue
6 March 2023 16:26
(Sharecast News) - Contract research organisation Fusion Antibodies issued a revenue warning on Monday, after a "challenging" first six months of trading as a number of valuable projects were...
-
Fusion Antibodies confident after 'challenging' first half
5 December 2022 16:28
(Sharecast News) - Contract research organisation Fusion Antibodies reported first-half revenues of £1.9m on Monday, down from £2.4m year-on-year.
-
Fusion Antibodies reports strong full-year revenue growth
6 May 2022 12:52
(Sharecast News) - Preclinical antibody discovery and supply company Fusion Antibodies reported 14% growth in revenue in a trading update on Friday, to £4.8m.
Company announcements Announcements
-
Approval of Grant Funding Application
4 December 2024 11:31
Fusion Antibodies
-
Half-year Report
19 November 2024 07:00
Fusion Antibodies
-
Director/PDMR Shareholding
16 October 2024 13:23
Fusion Antibodies
-
Issue of shares to non-executive directors
16 October 2024 07:00
Fusion Antibodies
-
Result of AGM
8 October 2024 12:32
Fusion Antibodies
-
AGM statement and trading update
8 October 2024 07:00
Fusion Antibodies
-
Block admission six monthly return
2 October 2024 07:00
Fusion Antibodies
-
Notice of AGM
12 September 2024 09:54
Fusion Antibodies
-
Director/PDMR Shareholding
9 September 2024 12:35
Fusion Antibodies
-
Director/PDMR Shareholding
5 September 2024 12:15
Fusion Antibodies
-
Final Results
5 September 2024 07:00
Fusion Antibodies
-
Director/PDMR Shareholding
22 July 2024 12:54
Fusion Antibodies
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.
© Digital Look Ltd 1998-2024. All rights reserved.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.